Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)
From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.
Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.
Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.
Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.
The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.
It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.
“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
https://cosmeticsbusiness.com/est%C3%A9e-lauder-targets-age-reversal-with-stanford-center
The Future Is Bright
To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.
Fortunately, the future’s looking bright with medical biotechnological advancements.
Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.
These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.
hTtps://genflowbio.com/premature-aging/
GenFlow Biosciences
1,399 followers
1h
At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF), we're passionate about unveiling the mysteries of aging. Our latest article dives deep into premature aging, offering valuable insights on how your lifestyle choices and genetic factors play a crucial role. Learn about the impacts on various body systems and get expert tips for staying youthful and healthy.
Read it here: htTps://loom.ly/565AscQ
#longevity #aging #healthspan
GenFlow Biosciences
1,399 followers
21h
In Sardinia, GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging in humans. Investigating its causes offers valuable insights into the aging process and may lead to strategies that enhance overall health and longevity.
Learn more about Werner here:
htTps://loom.ly/RcDWpwk #Werner #longevity #aging #healthspan
The date in the URL link below is November 2023, no doubt following the news of the appointment of the Joint Broker, and as good news could drop at anytime , it looks like there's going to be plenty of UPward momentum in sp in anticipation...Excitement building!!! Gl ;-)
When was that presentation released MM ?
Genflow Corporate Power Point Presentation
hTtps://genflowbio.com/wp-content/uploads/2023/11/GENF.corporate.US_.v1sm.pdf
The FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an announcement of a JV Veterinary partner. Gla ;-)
29/11/3
A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.
Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.
The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.
hTtps://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php
I got a feeling we will all be reading this, jam tomorrow mid 2024
Time they were putting some meat on the bone
Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)
Great rise, but this is nothing compared to what is to come!
GLA
Looking good and strong with news expected soon, which could add significant value. Gla holders :-)
Good to see a company so on point with its social media munch. I enjoy watching their LinkedIn updates, as well as seeing the calibre of industry experts who like their posts, affirming that Genf are seen as fellow industry leaders in the field of longevity.
I was thinking more about the relevance with SIRT6 and food. We spend a fortune every year buying produce because it says organically reared. What would people pay for meat such as cow and chickens, if they’re reared on SIRT6 nutrients, as we all know we are what we eat and surely consumers would be happy to pay a premium for food enrichment that could prolong a healthy lifespan?
GenFlow Biosciences
1,386 followers
13h
Investing in GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) offers a unique opportunity to support pioneering work in the longevity field. Our company focuses on developing novel therapeutics that target the aging process, including our lead compound GF-1002, which is based on a centenarian variant of the SIRT6 gene. This innovative approach aims to extend both healthspan and lifespan, addressing the global challenge of aging and its associated health and economic impacts.
Learn more here: hTtps://loom.ly/MeQymHs
#GENF #longevity #healthspan #SIRT6
Agree munch. The pharma market is off to a hot start for 2024, and the team have so much to showcase. The company has been operating under radar, but things certainly look set to change, especially as more and more people become obsessed with the maintenance of good health, as our population gets older and older.
Money- it’s about time to on all fronts. Huge appetite for bio companies just now.
GLA
Harley there is a group, if you go on twitter and type #genf you’ll be able to find it, as it won’t show the pathway here if I type it.
Cheers Porter, and full market interest can't be far off Northeast, and I'm sure Eric is ready to deliver a flow of positive news....the Biotech sector at long last could be ready for some serious UPside and market appreciation, judging by today's Top risers board and Genflow's tiny market offers tremendous UPside potential. Gl :-)
Is there a group??
Fantastic read. One day the market will get what we are all about
GLA
Lovely find Munch. May explain the sudden jump in share price.
Great to see the company being recognised as one to be watched for the life changing science it can offer!
The Gaurdian....Company to Watch 2024!!!
4th January 2024
Genflow Biosciences
Longevity is not just for billionaires, says Dr Eric Leire, the founder and chief executive of Genflow Biosciences, which in December 2022 became the first anti-ageing biotech to list in Europe.
The London-listed and headquartered company, which has its labs in Belgium and an office in Cambridge, Massachusetts, is developing gene therapies for longer, healthier lives.
The company’s work is based on a rare mutation of the SIRT6 gene found in people who live beyond the age of 100, which was discovered by Dr Vera Gorbunova’s team at the University of Rochester in 2019. She chairs Genflow’s scientific advisory board.
“Some people are lucky to have the good gene, and what we want to do is share that luck with everybody,” says Leire, who previously worked for Pfizer and Schering-Plough.
Genflow plans to test an experimental therapy on people with an age-related liver disease called NASH in early 2025. It is also developing a therapy for Werner syndrome, a rare accelerated ageing disease, by which SIRT6 messenger RNA delivers the gene to the skin. Genflow is also launching a programme to prevent age-related loss of muscle mass, funded by new research grants.
It started trading on the OTCQB venture market in the US in the summer, to expand its reach to US investors. As an early-stage biotech, Genflow is a risky investment; its London-listed shares have lost nearly 90% of their value in the first year of trading. But it is certainly one to watch. The longevity science sector is forecast to reach $2bn (£1.6bn) by 2030, according to Insight Analytics. Julia Kollewe
Much more to come Porter...A very Bright and Happy New Year!!! :-)
0 0 0
GenFlow Biosciences
1,380 followers
3m
GenFlow Biosciences (LSE: GENF) (OTCQB: GENFF) is thrilled to be named "a firm to watch" by the The Guardian today.
As clinical trials for patients suffering from NASH get underway in 2025, we are very excited for 2024 and beyond.
Read the article here: hTtps://loom.ly/PWx_em8 #GENF #longevity #healthspan #SIRT6 #smallcaps #companytowatch
Lovely start to the year Munch.
Also seeing some decent articles popping up on Longevity, with Phil Newman noting family offices have a particular interest in the sector.
The below article released yesterday also notes:
"In the third quarter of 2023, the US contributed to 65% of all deals in the longevity sector, a report revealed, but Europe is getting involved as well. France and Switzerland made up 23% of total deals, with the UK at 5%."
https://sifted.eu/articles/new-year-longer-life-what-longevity-has-to-offer-in-2024
I'm certainly glad to be invested before the ship departs :)